Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2014 Sep 15;2014(9):ED000090.
doi: 10.1002/14651858.ED000090.

A clearer view of evidence in treating macular degeneration: off-label policies and independent research

Giulio Formoso  1 , Anna Maria Marata, Nicola Magrini, Lisa Bero
Affiliations
Editorial

A clearer view of evidence in treating macular degeneration: off-label policies and independent research

Giulio Formoso et al. Cochrane Database Syst Rev. .
No abstract available

PubMed Disclaimer

References

    1. Italian Competition Authority. Pharmaceuticals and antitrust: the Italian Competition Authority fines Roche and Novartis over Eur 180 million for cartelizing the sales of two major ophthalmic drugs, Avastin and Lucentis. www.agcm.it/en/newsroom/press‐releases/2106‐i760‐pharmaceuticals‐and‐ant... (accessed 10 September 2014).
    1. Italian Competition Authority. Proceedings of the Italian Competition Authority against Roche and Novartis. www.agcm.it/stampa/news/6799‐farmaci‐antitrust‐sanziona‐roche‐e‐novartis... [in Italian] (accessed 10 September 2014).
    1. Epstein P. Trials that matter: two faces of progress in the treatment of age‐related macular degeneration. Annals of Internal Medicine 2007;146:532–534. doi.org/10.7326/0003‐4819‐146‐7‐200704030‐00011 - PubMed
    1. CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, et al. Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine 2011;364(20):1897–908. doi.org/10.1056/NEJMoa1102673 - PMC - PubMed
    1. IVAN study investigators, Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology 2012;119(7):1399–411. doi.org/10.1016/j.ophtha.2012.04.015 - PubMed

Publication types

MeSH terms

LinkOut - more resources